Cargando…

Safety, tolerability, and efficacy of metformin extended-release oral antidiabetic therapy in patients with type 2 diabetes: An observational trial in Asia

BACKGROUND: The aim of the present prospective observational study was to assess the tolerability and antihyperglycemic efficacy of metformin extended-release (MXR) in the routine treatment of patients with type 2 diabetes mellitus (T2DM) from six Asian countries. METHODS: Data from 3556 patients tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Chul-Hee, Han, Kyung-Ah, Oh, Han-Jin, Tan, Kevin Eng-Kiat, Sothiratnam, Radhakrishna, Tjokroprawiro, Askandar, Klein, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549486/
https://www.ncbi.nlm.nih.gov/pubmed/22742083
http://dx.doi.org/10.1111/j.1753-0407.2012.00220.x
_version_ 1782256429323780096
author Kim, Chul-Hee
Han, Kyung-Ah
Oh, Han-Jin
Tan, Kevin Eng-Kiat
Sothiratnam, Radhakrishna
Tjokroprawiro, Askandar
Klein, Marcus
author_facet Kim, Chul-Hee
Han, Kyung-Ah
Oh, Han-Jin
Tan, Kevin Eng-Kiat
Sothiratnam, Radhakrishna
Tjokroprawiro, Askandar
Klein, Marcus
author_sort Kim, Chul-Hee
collection PubMed
description BACKGROUND: The aim of the present prospective observational study was to assess the tolerability and antihyperglycemic efficacy of metformin extended-release (MXR) in the routine treatment of patients with type 2 diabetes mellitus (T2DM) from six Asian countries. METHODS: Data from 3556 patients treated with once-daily MXR for 12 weeks, or until discontinuation, were analyzed. RESULTS: Treatment with MXR was well tolerated, with 97.4% of patients completing 12 weeks of treatment. Only 3.3% of patients experienced one or more gastrointestinal (GI) side-effects and only 0.7% of patients discontinued for this reason (primary endpoint). The incidence of GI side-effects and related discontinuations appeared to be considerably lower during short-term MXR therapy than during previous treatment (mean 2.71 years’ duration), most commonly with immediate-release metformin. A 12-week course of MXR therapy also reduced HbA1c and fasting glucose levels from baseline. CONCLUSIONS: The present study provides new insights into the incidence of GI side-effects with MXR in Asian patients with T2DM and on the tolerability of MXR in non-Caucasian populations. Specifically, these data indicate that once-daily MXR not only improves measures of glycemic control in Asian patients with T2DM, but also has a favorable GI tolerability profile that may help promote enhanced adherence to oral antidiabetic therapy.
format Online
Article
Text
id pubmed-3549486
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-35494862013-01-22 Safety, tolerability, and efficacy of metformin extended-release oral antidiabetic therapy in patients with type 2 diabetes: An observational trial in Asia Kim, Chul-Hee Han, Kyung-Ah Oh, Han-Jin Tan, Kevin Eng-Kiat Sothiratnam, Radhakrishna Tjokroprawiro, Askandar Klein, Marcus J Diabetes Asia Track BACKGROUND: The aim of the present prospective observational study was to assess the tolerability and antihyperglycemic efficacy of metformin extended-release (MXR) in the routine treatment of patients with type 2 diabetes mellitus (T2DM) from six Asian countries. METHODS: Data from 3556 patients treated with once-daily MXR for 12 weeks, or until discontinuation, were analyzed. RESULTS: Treatment with MXR was well tolerated, with 97.4% of patients completing 12 weeks of treatment. Only 3.3% of patients experienced one or more gastrointestinal (GI) side-effects and only 0.7% of patients discontinued for this reason (primary endpoint). The incidence of GI side-effects and related discontinuations appeared to be considerably lower during short-term MXR therapy than during previous treatment (mean 2.71 years’ duration), most commonly with immediate-release metformin. A 12-week course of MXR therapy also reduced HbA1c and fasting glucose levels from baseline. CONCLUSIONS: The present study provides new insights into the incidence of GI side-effects with MXR in Asian patients with T2DM and on the tolerability of MXR in non-Caucasian populations. Specifically, these data indicate that once-daily MXR not only improves measures of glycemic control in Asian patients with T2DM, but also has a favorable GI tolerability profile that may help promote enhanced adherence to oral antidiabetic therapy. Blackwell Publishing Ltd 2012-12 /pmc/articles/PMC3549486/ /pubmed/22742083 http://dx.doi.org/10.1111/j.1753-0407.2012.00220.x Text en © 2012 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and Wiley Publishing Asia Pty Ltd http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
spellingShingle Asia Track
Kim, Chul-Hee
Han, Kyung-Ah
Oh, Han-Jin
Tan, Kevin Eng-Kiat
Sothiratnam, Radhakrishna
Tjokroprawiro, Askandar
Klein, Marcus
Safety, tolerability, and efficacy of metformin extended-release oral antidiabetic therapy in patients with type 2 diabetes: An observational trial in Asia
title Safety, tolerability, and efficacy of metformin extended-release oral antidiabetic therapy in patients with type 2 diabetes: An observational trial in Asia
title_full Safety, tolerability, and efficacy of metformin extended-release oral antidiabetic therapy in patients with type 2 diabetes: An observational trial in Asia
title_fullStr Safety, tolerability, and efficacy of metformin extended-release oral antidiabetic therapy in patients with type 2 diabetes: An observational trial in Asia
title_full_unstemmed Safety, tolerability, and efficacy of metformin extended-release oral antidiabetic therapy in patients with type 2 diabetes: An observational trial in Asia
title_short Safety, tolerability, and efficacy of metformin extended-release oral antidiabetic therapy in patients with type 2 diabetes: An observational trial in Asia
title_sort safety, tolerability, and efficacy of metformin extended-release oral antidiabetic therapy in patients with type 2 diabetes: an observational trial in asia
topic Asia Track
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549486/
https://www.ncbi.nlm.nih.gov/pubmed/22742083
http://dx.doi.org/10.1111/j.1753-0407.2012.00220.x
work_keys_str_mv AT kimchulhee safetytolerabilityandefficacyofmetforminextendedreleaseoralantidiabetictherapyinpatientswithtype2diabetesanobservationaltrialinasia
AT hankyungah safetytolerabilityandefficacyofmetforminextendedreleaseoralantidiabetictherapyinpatientswithtype2diabetesanobservationaltrialinasia
AT ohhanjin safetytolerabilityandefficacyofmetforminextendedreleaseoralantidiabetictherapyinpatientswithtype2diabetesanobservationaltrialinasia
AT tankevinengkiat safetytolerabilityandefficacyofmetforminextendedreleaseoralantidiabetictherapyinpatientswithtype2diabetesanobservationaltrialinasia
AT sothiratnamradhakrishna safetytolerabilityandefficacyofmetforminextendedreleaseoralantidiabetictherapyinpatientswithtype2diabetesanobservationaltrialinasia
AT tjokroprawiroaskandar safetytolerabilityandefficacyofmetforminextendedreleaseoralantidiabetictherapyinpatientswithtype2diabetesanobservationaltrialinasia
AT kleinmarcus safetytolerabilityandefficacyofmetforminextendedreleaseoralantidiabetictherapyinpatientswithtype2diabetesanobservationaltrialinasia